Jci_page_head_homepage_01 Jci_page_head_homepage_02
Jennifer A. Hendrix, Brian R. Wamhoff, Oliver G. McDonald, Sanjay Sinha, Tadashi Yoshida, Gary K. Owens
Published in Volume 115, Issue 2
J Clin Invest. 2005; 115(2):418–427 doi:10.1172/JCI22648
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 3

Oligonucleotides containing the c-fos SRE consensus CArG substitution competed for SRF binding activity more effectively than did wild-type SM α-actin oligonucleotides (containing CArG-A and/or CArG-B) in EMSAs. (A) In vitro translated SRF and a 95-bp radiolabeled probe harboring the CArG-containing region of the SM α-actin promoter were used for EMSAs. Unlabeled 95-bp double-stranded oligonucleotides containing either the SM α-actin 5′ CArGs (WT) or the SRE consensus CArG substituted for CArG-A (SRE-A), CArG-B (SRE-B), or CArG-A and CArG-B (SRE-AB) in the context of the SM α-actin promoter were used as cold competitors at approximately 50-, 100-, and 200-fold excess over labeled probe. The SRE CArG in the context of the c-fos promoter (fos) was used as a cold competitor at approximately 50-fold excess over labeled probe. The SRF band was supershifted (SRF SS) by the addition of 2 μg of anti-SRF rabbit polyclonal antibody. Unprog. lysate, unprogrammed control lysate. (B) Densitometry was performed on the SRF bands (see Figure 5A) and results were plotted relative to maximal SRF binding to the radiolabeled probe in the absence of cold competitor. Results are representative of 3 independent experiments. Statistical analyses were performed using 1-way ANOVA. We found statistically significant differences between percentage of SRF binding in the presence of WT cold competitor and percentage of SRF binding in the presence of SRE-AB, SRE-A, or SRE-B cold competitor under all but 1 condition (×50 WT versus ×50 SRE-AB) across multiple experiments (data not shown).